Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
66.2M
-
Shares change
-
+17.1M
-
Total reported value, excl. options
-
$59.5M
-
Value change
-
+$14.5M
-
Put/Call ratio
-
0
-
Number of buys
-
26
-
Number of sells
-
-38
-
Price
-
$0.90
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q2 2022
84 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q2 2022.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66.2M shares
.
Largest 10 shareholders include BROADWOOD CAPITAL INC (23.4M shares), PURA VIDA INVESTMENTS, LLC (18.1M shares), AWM Investment Company, Inc. (7.75M shares), VANGUARD GROUP INC (4.35M shares), ORBIMED ADVISORS LLC (2.84M shares), Defender Capital, LLC. (2.59M shares), MILLENNIUM MANAGEMENT LLC (996K shares), GEODE CAPITAL MANAGEMENT, LLC (973K shares), Schonfeld Strategic Advisors LLC (957K shares), and Penbrook Management LLC (576K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.